Search Type: drug or dietary supplement name
Search Term: liraglutide (SAXENDA, VICTOZA)
| Worst Pills, Best Pills Newsletter Articles |
Search
results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion
-
Incretin-Mimetic Drugs: Do Not Use to Treat Diabetes
[hide all summaries]
(August 2016)
Incretin mimetics, one of the newer classes of diabetes drugs, are widely prescribed in the U.S. Find out why Public Citizen's Health Research Group recommends against using any of these medications. -
Liraglutide (SAXENDA) for Weight Loss
[hide all summaries]
(October 2015)
Find out why the recently approved high-dose form of liraglutide, which was originally marketed for treatment of Type 2 diabetes, is not a safe option for managing weight loss -
Public Citizen Shines a Light on Off-Label Promotion of Diabetes Drugs
[hide all summaries]
(July 2015)
In a recent complaint to the FDA, we took several makers of diabetes drugs to task for direct-to-consumer ads that promote the drugs for unapproved uses. Find out the names of the drugs targeted in our complaint and the nature of the off-label uses being promoted in the ads. -
Diabetes Drugs Linked to Pancreas Disease
[hide all summaries]
(August 2013)
Six recently approved diabetes drugs have been linked to an increased risk of pancreatitis and possibly pancreatic cancer. -
Correction: 'Liraglutide (VICTOZA): Add Another One to the List of "Do Not Use" Drugs for Type-2 Diabetes'
[hide all summaries]
(July 2011)
There was an error in a paragraph describing interpretation of the results of the blood test hemoglobin A1c (HbA1c), which is used to assess the body’s control of sugar (glucose). -
Review of Type-2 Diabetes Medication Liraglutide (VICTOZA)
[hide all summaries]
(April 2011)
This article reviews the safety and efficacy of liraglutide (VICTOZA), a new medication used to treat type-2 diabetes. -
Saxagliptin (ONGLYZA) - Another Diabetes Drug
[hide all summaries]
(February 2011)
This article discusses why you should not use this newly approved diabetes drug until more is known about its safety.
Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion
-
Testimony before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Liraglutide for Weight Loss (HRG Publication #2219)
[hide all summaries]
Public Citizen strongly opposes the approval of liraglutide (Saxenda) for weight loss because the drug, currently approved for type 2 diabetes, has already been shown to be toxic at a lower dose than that which is being considered for weight loss, while conferring only marginal benefits on weight reduction and no proven long-term health benefits. -
Acute Pancreatitis With Liraglutide: An analysis of MedWatch adverse event reports submitted to the Food and Drug Administration (HRG Publication #2204)
[hide all summaries]
A new Public Citizen study referenced in a letter sent to the U.S. Food and Drug Administration (FDA), and posted online, reinforces the case that the diabetes drug liraglutide can cause pancreatitis and should be banned immediately by the FDA. -
Petition to Ban Diabetes Drug Liraglutide (Victoza) (HRG Publication #2020)
[hide all summaries]
Public Citizen petitions the Food and Drug Administration (FDA) to immediately remove from the market the diabetes drug liraglutide (Victoza; Novo Nordisk) because the known increased risks of thyroid cancer and pancreatitis outweigh any documented clinical benefits.
SHOW secondary search results for liraglutide (SAXENDA, VICTOZA)
Copyright © 2018 Public Citizen's Health Research Group. All rights reserved.
https://www.worstpills.org/